welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina’s nucleic acid therapeutics assets.
expertly curated content related to this topic
-
How do patients with rare Diseases Experience the Medical Encounter? Exploring Role Behavior and its Impact on Patie...OBJECTIVES: Empirical research shows th...
-
Robert S. Sandler, MD, MPHNina and John Sessions Distinguished Pro...
-
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous P...RATIONALE: Chemoprevention is the us...
-
#hereditarycoloncancerFAP hashtag for the community...
-
UPMC MercyPatient Resource: Center for Counseling...
-
@hopelovefaith30Laughter, Friendship, Snacks & Tequi...
-
East Belfast father and son using their love of cars to raise thousands for sick youngsterIain Craig and son Jacob are organising ...